Outset Medical (OM) EBIAT (2019 - 2025)
Outset Medical (OM) has disclosed EBIAT for 7 consecutive years, with -$19.5 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 24.05% to -$19.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$81.7 million, a 36.21% increase, with the full-year FY2025 number at -$81.7 million, up 36.21% from a year prior.
- EBIAT was -$19.5 million for Q4 2025 at Outset Medical, down from -$17.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$17.8 million in Q3 2025 to a low of -$46.2 million in Q3 2023.
- A 5-year average of -$33.9 million and a median of -$35.7 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 45.4% in 2021, then skyrocketed 46.19% in 2025.
- Outset Medical's EBIAT stood at -$41.2 million in 2021, then fell by 0.62% to -$41.5 million in 2022, then increased by 6.89% to -$38.6 million in 2023, then soared by 33.52% to -$25.7 million in 2024, then rose by 24.05% to -$19.5 million in 2025.
- Per Business Quant, the three most recent readings for OM's EBIAT are -$19.5 million (Q4 2025), -$17.8 million (Q3 2025), and -$18.5 million (Q2 2025).